中文速读
在HCC细胞Huh7和PLC/PRF/5中,使用Entranster-R4000转染siRNA敲低ACSL3,研究ACSL3对索拉非尼耐药和铁死亡的影响。
体外(细胞)siRNAHuh7PLC/PRF/5
Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC
Affiliations
- 1 School of Basic Medicine, Qingdao University, Qingdao, China.
- 2 Qingdao Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
- 3 Biomedical center, Qingdao university, Qingdao, China.
- 4 Hepatobiliary Surgery Department 1, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
- 5 Department of Clinical Laboratory, Maternity and Child Care Hospital, Weifang, China.
- 6 Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
- PMID: 39744125
- PMCID: PMC11688200
- DOI: 10.3389/fphar.2024.1464852
Abstract
Background: Sorafenib is a first-line treatment for hepatocellular carcinoma (HCC); however, acquired resistance often results in a poor prognosis, indicating a need for more effective therapies. Sorafenib induces cell death through an iron-dependent mechanism known as ferroptosis, which is closely associated with the onset and progression of HCC.
Methods: This study investigated the role of ACSL3 in sorafenib resistance and ferroptosis in HCC. The expression of ACSL3 was analyzed in HCC tissues and cell lines. Ferroptosis levels and cell viability were assessed in ACSL3-silenced HCC cells treated with sorafenib. The regulatory relationship between the transcription factor MEF2D and ACSL3 was evaluated using promoter binding assays and gene expression analysis.
Results: ACSL3 was aberrantly expressed in HCC and promoted the progression of non-alcoholic fatty liver disease (NAFLD) to HCC. Elevated ACSL3 expression inhibited ferroptosis and enhanced resistance to sorafenib. The transcription factor MEF2D directly regulated the upregulation of ACSL3 expression. MEF2D bound to the promoter regions of ACSL3 to enhance its transcription and negatively regulate ferroptosis in HCC.
Conclusion: This study demonstrated for the first time that MEF2D regulated ACSL3 expression and mediated sorafenib resistance by inhibiting ferroptosis in HCC, providing a potential therapeutic target for improving HCC outcomes.
Keywords: ACSL3; HCC; MEF2D; ferroptosis; sorafenib resistance.
小核酸转染试剂Entranster™-R4000 已有 223 篇已发表文献
同类研究
- J Ovarian Res. 2026 Jul 31;19(1):330.doi: 10.1186/s13048-026-02215-6. Microfluidic lipid nanoparticles co-delivering siM…
- Front Immunol. 2026 May 29;17:1724930.doi: 10.3389/fimmu.2026.1724930. Machine learning-based identification of an oxida…
- Cell Calcium. 2026 Apr 19:135:103137.doi: 10.1016/j.ceca.2026.103137. TRPC1 channel modulates mechanical stretch-induced…
- Pharmaceuticals (Basel). 2026 Mar 27;19(4):540.doi: 10.3390/ph19040540. Identification of Dopamine D2 Receptor as a Dire…
- Viruses. 2026 Mar 5;18(3):323.doi: 10.3390/v18030323. Tree Shrew Genome-Wide CRISPR Screen Identifies RNF6 as a Proviral…